Back to Results
First PageMeta Content
Lemelson–MIT Prize / Biotechnology / Robert S. Langer / Taris / Flybridge Capital Partners / Interstitial cystitis / Cystitis / Overactive bladder / Bladder cancer / Medicine / Health / Urology


TARIS CLOSES $18.3 MILLION SERIES B FINANCING -- Third Rock Ventures Leads Round -Lexington, MA – April 13 , 2011 – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, ta
Add to Reading List

Document Date: 2011-04-13 07:09:59


Open Document

File Size: 467,17 KB

Share Result on Facebook
UPDATE